Pancreatic Ductal Adenocarcinoma Overview

Save information for later
Sign Up

Learn About Pancreatic Ductal Adenocarcinoma

What is the definition of Pancreatic Ductal Adenocarcinoma?
Pancreatic ductal adenocarcinoma is an aggressive cancer that occurs in the linings of the tubes of the pancreas that carry enzymes to the intestines that assist with digestion.
What are the symptoms of Pancreatic Ductal Adenocarcinoma?
Early pancreatic ductal adenocarcinoma may not have any symptoms. Symptoms of pancreatic ductal adenocarcinoma may include yellowing of the skin and whites of the eyes, fatigue, dark urine, light-colored or greasy stools, itchy skin, abdominal or back pain, weight loss, nausea and vomiting, gallbladder or liver enlargement, blood clots, and diabetes.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Pancreatic Ductal Adenocarcinoma?
Treatment for pancreatic ductal adenocarcinoma includes surgery, radiation therapy, and chemotherapy.
Who are the top Pancreatic Ductal Adenocarcinoma Local Doctors?
Elite in Pancreatic Ductal Adenocarcinoma
Dr. Jason B. Fleming
Surgical Oncology | General Surgery
Elite in Pancreatic Ductal Adenocarcinoma
Dr. Jason B. Fleming
Surgical Oncology | General Surgery

University Of Texas Southwestern Medical Center At Dallas

6201 Harry Hines Blvd, 
Dallas, TX 
214-633-5555
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jason Fleming is a Surgical Oncologist and a General Surgeon in Dallas, Texas. Dr. Fleming is rated as an Elite provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Elite in Pancreatic Ductal Adenocarcinoma
Dr. Ben A. George
Oncology | Hematology Oncology | Hematology
Elite in Pancreatic Ductal Adenocarcinoma
Dr. Ben A. George
Oncology | Hematology Oncology | Hematology

The Medical College Of Wisconsin Inc

8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
414-805-3666
Languages Spoken:
English, Malayalam
See accepted insurances
Accepting New Patients
Offers Telehealth

Ben George is an Oncologist and a Hematologist Oncology provider in Milwaukee, Wisconsin. Dr. George is rated as an Elite provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Pancreatectomy, and Gallbladder Removal. Dr. George is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Daniel J. Renouf
Elite in Pancreatic Ductal Adenocarcinoma
Daniel J. Renouf
Elite in Pancreatic Ductal Adenocarcinoma
Daniel J. Renouf
Vancouver, BC, CA 

Daniel Renouf practices in Vancouver, Canada. Mr. Renouf is rated as an Elite expert by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Familial Pancreatic Cancer, and Colorectal Cancer.

View All Doctors
What are the latest Pancreatic Ductal Adenocarcinoma Clinical Trials?
A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3

Summary: Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3

Summary: The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosphorylase (MTAP) deletion.

View All Clinical Trials